← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
CMH intratympanic dexamethasone/lignocaine tinnitus study
Also known as: Dexamethasone with lignocaine for tinnitus, NCT04798391
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Phase 4
Status
Unknown
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
70%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Pakistan
Population
adult, tinnitus, study-level
Trial IDs
1
Mechanism
Single-group Phase 4 study of intratympanic dexamethasone plus lignocaine injections for idiopathic unilateral tinnitus severity.
Indications
Notes
Split out from the broad dexamethasone cluster. ClinicalTrials.gov verifies a Combined Military Hospital Pakistan single-group tinnitus study; registry status is Unknown and no commercial sponsor is identified.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT04798391
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-verified-studycurrent-status-unknown-in-registrygeneric-drug-studystudy-level-not-standalone-productnot-commercial-pipeline-program
Related Programs
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
OTO-313 by Otonomy
Company: Otonomy · Small Molecule · Phase 2
AM-101 by Auris Medical and Altamira
Company: Altamira Therapeutics · Small Molecule · Phase 3
NHPN-1010
Company: Otologic Pharmaceutics · Small Molecule · Phase 1
OTO-104 (dexamethasone) by Otonomy
Company: Otonomy · Steroid/Anti-inflammatory · Phase 3